The quarter missed a high bar by a wide margin. CF delivered diluted EPS of $4.73 versus published consensus estimates around $5.6-$5.8, while revenue of $2.22 billion trailed expectations near $2.5 billion.
| Metric | Q2 2026 | Q2 2025 | Market expectation |
|---|---|---|---|
| Net sales | $2.22 billion (Consolidated Results) | $1.89 billion (Consolidated Results) | ~$2.47-$2.53 billion, published consensus |
| Diluted EPS | $4.73 (Consolidated Results) | $2.37 (Consolidated Results) | ~$5.63-$5.79, published consensus |
| Adjusted EBITDA | $1.19 billion (Consolidated Results) | $761 million (Consolidated Results) | Not provided |
| Gross margin | $1.15 billion; 51.5% (Consolidated Results) | $755 million; 39.9% (Consolidated Results) | Not provided |
| Sales volume | 4.252 million tons (Consolidated Results) | 5.021 million tons (Consolidated Results) | Not provided |
- Pricing and mix were powerful, but product availability was the constraint. Revenue rose 18% year over year despite a 15% volume decline because selling prices improved across every major segment. Granular urea was the standout, with adjusted gross margin per product ton rising to $430 from $295; UAN also improved sharply to $290 from $180. (Segment results — Granular urea; Segment results — UAN)
- The operating result was better than the headline EPS, but still not enough versus expectations. Q2 adjusted EBITDA nearly doubled year over year to $1.19 billion, and gross margin expanded to 51.5%. However, the market was already expecting a very strong nitrogen-price environment; the shortfall in sales volumes, particularly UAN, ammonia and AN, outweighed the pricing benefit. AN remained loss-making, with adjusted gross margin of negative $1 million. (Consolidated Results; Segment results — AN)
- The miss was operational rather than caused by the litigation gain. The approximately $170 million litigation settlement gain benefited the first half, not the second quarter. First-half EPS of $8.71 therefore overstates recurring earnings, while first-half sales volumes fell 11% and the Yazoo City outage remains a meaningful supply limitation. (Comparability items; Consolidated Results; Management discussion)
- The outlook is constructive but not a fresh upside surprise. Management continues to expect 9.5 million tons of 2026 ammonia production, Yazoo City’s restart in the first half of 2027, and roughly $950 million of CF-funded 2026 capital expenditures. Blue Point construction is now commencing after permits were issued, but it also raises near-term spending; total 2026 capital expenditures are projected at about $1.3 billion. (Management outlook; Capital expenditures)
Net read: negative versus expectations. CF is generating unusually strong margins and cash flow, but this filing says the market expected even more. Lower volumes, the unresolved Yazoo outage and a large revenue/EPS miss outweigh the healthy pricing environment and Blue Point progress.
Read the original 8-K on SEC EDGAR ↗